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Abstract
Postprandial lipemia (PPL) is characterized by prolonged and increased levels 
of lipids especially triglycerides (TG) and triglyceride-rich lipoprotein levels after 
a meal. There are an increasing number of evidence that postprandial lipemia is 
a significant risk factor for cardiovascular disease because of its causative role in 
atherosclerosis and endothelial dysfunction. This has serious implications because 
common dietary patterns are characterized by high fat content and meal consump-
tion; hence, most will be in a postprandial state resulting to frequent and pro-
longed exposure to high lipid levels. The review will present the current evidences 
for the role of postprandial lipemia as a risk factor for cardiovascular disease and 
its association with other cardiovascular risk factors, namely, diabetes and obe-
sity. We will also present recommendations on the diagnosis and management of 
postprandial lipemia.
Keywords: postprandial lipemia, postprandial dyslipidemia, endothelial 
dysfunction, hypertriglyceridemia
1. Lipoprotein metabolism
Lipoproteins are responsible for the distribution of cholesterol and triglyc-
eride from the intestine and liver to peripheral cells. The process of lipoprotein 
distribution and metabolism is highly related to energy metabolism and the 
feed-fast cycle. Triglycerides (TG) are synthesized from dietary free fatty acids 
and glycerol in enterocytes. They are assembled together with phospholipids and 
cholesterol with apolipoproteins, mainly apoB-48 into chylomicron particles (apo 
A, C, E also present). These TG-rich particles enter the plasma via the intestinal 
lymph. Chylomicrons are then transported to peripheral cells where the enzyme 
lipoprotein lipase (LPL) hydrolyses their triglyceride content, releasing free 
fatty acids to be used by peripheral cells. The resulting chylomicron remnants are 
smaller and denser and are removed in the circulation by binding of the surface 
apo E to the LDL receptor or LDL receptor-related protein (LRP) [1]. Please also 
refer to the introductory chapter of this book for detailed and illustrated review 
of lipoprotein metabolism.
In the liver, synthesized TGs are released to the circulation by the very low-
density lipoprotein (VLDL) particles. VLDL particles are TG-rich and, mainly, apo 
B-100-containing particles (apo A, C, E also present). VLDL synthesis takes place 
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during fasting and prandial state. Once delivered to peripheral tissues, the TG 
contents are hydrolyzed to free fatty acids by LPL, similar to that of chylomicrons. 
VLDL remnants, also called intermediate-density lipoproteins (IDL), are taken up 
by the liver via apo E binding to LDL receptor or converted to LDL by removal of 
TG content by the hepatic triglyceride lipase (HTGL) enzyme. The removal of TG 
renders the particles smaller allowing better vascular penetration, hence increas-
ing atherogenicity [2].
The cholesterol ester transfer protein (CETP) facilitates the transfer of choles-
teryl esters from high-density lipoproteins (HDL) particles to VLDL in exchange for 
TGs. Cholesteryl ester-enriched particles are better substrates for HTGL allowing 
greater decrease in size of the particle, creating small dense (sd) LDL. Small, dense 
LDL are more atherogenic due to their smaller size as they readily enter the suben-
dothelial space [1].
Chylomicrons, VLDL, and their respective remnants (remnant lipoproteins 
(RLP)) are termed triacylglycerol-rich lipoproteins (TRL) (Figure 1).
2. Lipid profile in the postprandial state
The plasma lipid levels normally fluctuate during the day, in response to food 
intake. TG levels vary more considerably compared to LDL and HDL cholesterol 
levels. Nowadays, the common dietary habit is characterized by high fat contents 
and high frequency of meals; hence, most individuals will be in a nonfasting 
state. Because of the evidence of association of nonfasting lipid levels as a risk 
factor for CVD, it is important to analyze postprandial lipoprotein physiology 
and metabolism [2].
In a study by Stanhope et al., it has been found that TG levels are significantly 
elevated during the day in association to food intake. When fructose was adminis-
tered, there was significant increase in TG compared with the regular meal. Plasma 
cholesterol levels did not significantly change during the day [3]. In our previous 
studies, we were able to demonstrate the pattern of postprandial lipid rise. We 
have found that there was significant increase in the levels for total cholesterol, 
Figure 1. 
Lipoprotein metabolism overview. Dietary TG transported via chylomicrons and hepatic TG transported via 
VLDL are delivered to peripheral tissue and acted upon by lipoprotein lipase to liberate fatty acids for energy 
fuel, cellular synthesis, or fat storage. Chylomicron and VLDL remnants are taken up by the liver. VLDL 
remnants can be further hydrolyzed by HTGL to form LDL particles.
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triglycerides, and HDL with peaking at the 4th–5th hour after a fatty meal [4]. The 
postprandial increase in TG is again demonstrated in another study by our group 
and has shown to be similar with VLDL postprandial increase beginning 4 hours 
after breakfast and sustained until 9–10 hours after [5]. In one of our trials, similar 
patterns of postprandial increase in TC, TG, and HDL were demonstrated with 
peaking at the 4th–5th hour and with noted decline at the 5th–6th hour [6]. None of 
our studies have demonstrated any pattern of postprandial rise for LDL.
The postprandial period is characterized by an increase in atherogenic lipopro-
tein particles. These are the TRLs including chylomicrons, VLDL, and their rem-
nant particles. Their levels are affected by multiple individual and environmental 
factors, including sex, age, body mass index, physical activity, and smoking, and by 
the amount and type of dietary fat in a meal [7].
In the study by Cohn et al., they have shown that there may be more than one 
peak in postprandial TG concentration, that the magnitude of postprandial rise 
is dependent on age and gender, that postprandial plasma cholesterol concentra-
tion can increase or remain at baseline, and that postprandial cholesterolemia is 
inversely correlated with fasting HDL levels [8].
The postprandial lipid response has been shown to be modified by polymor-
phisms within the genes for apo A-I, E, B, C-I, C-III, A-IV, and A-V, LPL, hepatic 
lipase, fatty acid-binding protein-2, the fatty acid transport proteins, microsomal 
triglyceride transfer protein, and scavenger receptor class B Type I [9].
3. Postprandial lipemia in diabetes
Diabetes is associated with premature atherosclerosis and cardiovascular 
disease, and this may be contributed to diabetic dyslipidemia. Diabetes is character-
ized by multiple lipoprotein metabolism abnormalities that promote atherogenesis. 
The common lipid abnormality in diabetes includes hypertriglyceridemia, low 
HDL, and increase in small, dense LDL (sdLDL) levels. In a study by Shukla that 
investigated the postprandial response of type 2 DM patients after a standard fat 
challenge, it has been found that compared to normal controls, DM patients have 
significantly higher postprandial triglyceride levels despite having similar fasting 
levels. No significant difference in postprandial HDL levels was seen when adjusted 
to fasting levels [10].
The abnormalities in lipids among diabetics are secondary to multiple metabolic 
derangement that characterizes diabetes. For example, it has also been found that 
intestinal lipoprotein metabolism among diabetics is altered with increased lipopro-
tein production that prolongs postprandial lipemia [11].
In our clinic-based retrospective study, we have found that HbA1c has strong 
positive correlation with postprandial TG, while the 2-hour plasma glucose has 
moderate positive correlation. These significant correlations of postprandial lipe-
mia with glycemic control and postprandial glycemia suggest that despite optimal 
fasting lipid levels, poor glycemic control is still associated with elevation of post-
prandial lipids, specifically postprandial triglycerides [12]. Similarly, Nakamura 
et al. have demonstrated that insulin resistance is closely related to postprandial 
hyperlipidemia among type 2 DM patients with CAD. Specifically, they have found 
that the 6th hour postprandial TG and remnant-like particle cholesterol were 
significantly higher among type 2 DM subjects and that plasma insulin levels and 
insulin resistance index were correlated with serum TG and RLP-C levels [13]. In 
addition, it has been shown in an animal study that postprandial hypertriglyceride-
mia predicts the development of insulin resistance, glucose intolerance, and type 2 
DM [14]. However, evidence is still lacking.
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Although it has been shown that glycemia is correlated with postprandial 
dyslipidemia, there are evidences that even with good glycemic control, diabetes is 
still associated with postprandial dyslipidemia. Rivellese et al. have demonstrated 
that subjects with type 2 DM with good glucose control and optimal fasting triglyc-
eride levels still presented with abnormal plasma lipid response after a standard 
mixed meal. In particular, large VLDL and chylomicron remnants were shown to be 
elevated postprandially [15].
4. Postprandial lipemia and obesity
Obesity is a global epidemic affecting both children and adults. It is commonly 
defined as a body mass index (BMI) of ≥30 kg/m2, but other indexes such as waist 
circumference and waist to hip ratio have been used. It is an established risk factor 
for cardiovascular disease, and it has been associated with dyslipidemia and abnor-
malities in lipoprotein metabolism. However, it is not yet established how obesity 
affects postprandial lipid levels.
Obesity is associated with insulin resistance, favoring catabolism and lipoly-
sis [16]. Hence, it may be expected that obesity is associated with postprandial 
lipemia. In our previous unpublished study, we have found that there was no 
significant difference in postprandial lipid response in obese subjects compared 
to normal-weight subjects. Interestingly, postprandial lipid levels were actually 
slightly lower in the obese group compared to the normal group. This study used 
BMI to classify obese subjects, and different results were seen in studies that 
focused on abdominal obesity. Abdominal obesity has been known to be a risk 
factor for cardiovascular disease [17], and it has been demonstrated that abdomi-
nal obesity is associated with prolonged and amplified postprandial lipid levels 
[18]. Interestingly, postprandial lipemia can be seen in abdominal obesity despite 
normal fasting levels of TG [18, 19].
5.  Role of postprandial lipemia in endothelial inflammation and 
dysfunction
Postprandial lipemia is hypothesized to be a risk factor for cardiovascular 
disease by inducing endothelial dysfunction [20]. The vascular endothelial lining 
functions to maintain adequate blood flow and regulate coagulation and inflamma-
tion. Endothelial dysfunction signifies any disturbance to the vasodilatory response 
of the endothelium and impairment of its antithrombotic and antiproliferative 
function [21]. This eventually translates to atherosclerosis and CVD. Several studies 
have shown that intake of high-fat meals can induce an increase in postprandial TG 
levels and impair endothelial function [22, 23].
Postprandial lipemia promotes atherogenesis and endothelial dysfunction 
by contributing to the inflammatory state in the endothelial environment [24]. 
Postprandial lipemia has also been shown in in vitro and in vivo studies to activate 
leukocytes promoting adherence to endothelial walls and migration to the suben-
dothelial space, therefore promoting atherosclerosis. VLDL, IDL, and chylomicron 
remnants have been shown to cause endothelial inflammation and promote increase 
in pro-inflammatory cells within the vascular walls. TG and TGRLs also induce 
pro-inflammatory cytokines that induce vascular cell adhesion molecule (VCAM)-1 
expression in endothelial cells and monocyte adhesion. Lipolysis of TGRLs by the 
enzyme lipoprotein lipase (LPL) along with the endothelium produces by-products 
that are pro-inflammatory and pro-atherogenic. Lipolysis produces oxidized free 
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fatty acids that promote endothelial inflammation, vascular apoptosis, and reactive 
oxygen species (ROS). Inflammation in the endothelium increases permeability and 
uptake of VDL in the vascular wall [25].
Maggi et al. have shown that postprandial levels of remnant lipoproteins 
(RLP) and TG contribute to endothelial dysfunction as measured by flow-
mediated dilatation (FMD) of the brachial artery. They have demonstrated that 
the increase in postprandial RLP and TG levels was associated to the decrease in 
FMD. In addition, the peak level of RLP at 6 hours after meal coincided with the 
maximal endothelial dysfunction [26]. Their findings are supported by similar 
Figure 2. 
The result from a study by Caringal et al. showing trends of lipid levels and brachial artery flow-mediated 
dilatation (FMD) after a standard diet.
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results in a study by Caringal et al. that investigated the relationship between 
postprandial lipid levels and endothelial dysfunction using FMD as surrogate 
marker. Five high-risk subjects with normal fasting lipid levels were given a stan-
dard low-fat diet. Interestingly, it was observed that even though the fasting lipid 
levels were normal, the peaking of TG and VLDL 6 hours postprandially and the 
decrease in HDL postprandially appear to coincide with the decrease in brachial 
artery FMD [27] (Figure 2).
A study by Giannattasio et al. involving 16 asymptomatic hypertriglyceridemic 
and 7 normotriglyceridemic controls showed attenuation of arterial vasodilatory 
response following a high-fat meal among subjects with dyslipidemia. This reflects 
postprandial impairment of endothelial function after a high-fat meal [23].
6. Postprandial lipemia and CV events
Lipid-lowering therapy focusing on LDL-C reduction has been proven to reduce 
coronary events and stroke [28]. However, with the evidences of association of 
postprandial lipemia, specifically TG and RLP with endothelial dysfunction, it is 
important to assess their role in morbidity and mortality.
In a prospective cohort by Nordertgaard et al., involving a large number of 
white women and men of Danish descent, they have found that elevated levels of 
nonfasting triglyceride were associated with increased risk for CV events. They 
have specifically demonstrated that increasing levels of nonfasting TG were associ-
ated with progressively increasing hazard ratio for myocardial infarction (MI), 
ischemic heart disease (IHD), and death. In addition, they have also demonstrated 
that remnant lipoprotein cholesterol increases as nonfasting TG increase [29]. A 
study by Bansal et al. further supports the role of TG in predicting CV events. They 
have demonstrated that both fasting and nonfasting TG are risks for CV events. 
However, because HDL-C level is a confounding variable, after adjusting to HDL-C, 
they have seen that compared to fasting TG, nonfasting TG has a stronger indepen-
dent relationship with cardiovascular events. Interestingly, they also demonstrated 
in secondary analyses that TG levels 2–4 hours postprandially had the strongest 
association with CV events [30]. This can be explained by the possibility that peak-
ing of endothelial dysfunction coincides with peaking of postprandial lipemia [26]. 
Also, most studies mentioned have noted that peaking of postprandial TG and RLPs 
occurred 4 hours after a meal [5, 6, 26, 27]. On the contrary, in a study by Kats et al. 
involving 559 participants who underwent oral fat challenge, they have found that 
none of the measures of postprandial change were associated with incident CVD 
events. However, the study is inadequately powered [31]. Hence, there is a need for 
more robust prospective studies to clearly demonstrate the role and extent of post-
prandial lipemia effect on CV events. At present, the evidences should be enough to 
effect change in the way me manage dyslipidemia.
7. Treatment
Optimal treatment goals for postprandial lipid levels that will result to risk 
reduction have not been determined. At present, most guidelines are focused on 
LDL-C reduction and use fasting lipid profile. LDL-C target goals also depend on 
risk stratification, with extremely high-risk patients recommended to decrease 
LDL-C to as low as 55 mg/dl and low-risk patients to <130 mg/dl [32].
Normal TG levels have been set to be <150 mg/dl during the fasting state [32]. 
In a study by White et al. that aimed to determine optimal nonfasting TG levels 
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involving middle-aged and older apparently healthy women, the diagnostic thresh-
old for nonfasting hypertriglyceridemia is seen to be at 175 mg/dL [33].
8. Diet
The importance of lifestyle modification cannot be overemphasized. Patients 
with dyslipidemia are advised to have reduced-calorie diet. Saturated and trans fats 
should also be minimized [32]. In addition, it has been found that a minimum of 
10 hours is needed for postprandial lipids to return to fasting or baseline levels [5]. 
Hence, to avoid prolonged exposure to elevated levels of postprandial lipids, fatty 
meals should be avoided or should at least be spaced 12 hours accordingly.
9. Statins
Statins are considered one of the first-line treatments for dyslipidemia. It has 
been established that statins are efficacious in lowering fasting lipids and that statin 
treatment has resulted to significant reductions in cardiovascular morbidity and 
mortality. Some studies also have proven that statins can be used to lower postpran-
dial lipid levels. However, in our study, we found that even on low fat diet, statin 
treatment, and normal fasting lipids, triglyceride and VLDL peaking and plateau-
ing were still observed in patients with cardiovascular disease [34]. Furthermore, 
Schaefer et al. did a comparative study among statins and their efficacy in lowering 
postprandial levels. They have found that atorvastatin was significantly more effec-
tive in lowering LDL cholesterol and non-high-density lipoprotein cholesterol than 
all other statins and significantly more effective than all statins, except for simvas-
tatin, in lowering triglyceride and remnant lipoprotein cholesterol. At 40 mg/day, 
atorvastatin was significantly more effective than all statins, except for lovastatin 
and simvastatin, in lowering cholesterol levels in small LDL, and was significantly 
more effective than all statins, except for simvastatin, in increasing cholesterol in 
large HDL and in lowering LDL particle numbers [35].
10. Fibrates
In a study by Cavallero et al., it has been found that fenofibrate normalized the 
abnormal postprandial response and improved the fasting lipoprotein abnormali-
ties in patients with type 2 diabetes [36]. This is supported by the study of Ooi et al., 
which showed that fibrate treatment resulted to a significant decrease in remnant 
lipoprotein levels postprandially [37].
11. Orlistat
A study by Turker et al. involving normolipidemic, obese women with normal 
glucose tolerance suggests that 12 weeks of treatment with orlistat 120 mg/d plus 
low-calorie diet was associated with a 4.1-fold change from baseline in PPL [38]. 
Abejuela et al. have shown that orlistat abolishes the peaking of TC, TG, and HDL 
after a 50% OFCT [6]. In a study by Gabriel et al. which compared the effects of 
orlistat on the postprandial lipid levels after sequential high-fat meals in healthy 
individuals with normal fasting lipid levels, they have seen that administration of 
orlistat abolished the significantly sustained postprandial rise of TG and VLDL levels 
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in healthy individuals who were fed sequential 50% fat meals. Specifically, they have 
seen that in the control group, there is a significant postprandial rise in the levels of 
TG and VLDL beginning at 4 hours after breakfast that was sustained until 9 hours 
for TG and up to 10 hours for VLDL postprandially. In contrast, only one significant 
rise in both TG and VLDL levels was noted in the group given orlistat [5].
12. Ezetimibe
Ezetimibe is usually given to statin-intolerant patients or used in combination 
with statin to lower cholesterol, primarily LDL. There are evidences that it can also 
improve postprandial lipemia. In a study by Bozetto et al., they have shown that 
ezetimibe when given with simvastatin produces greater decrease in LDL cholesterol 
compared to simvastatin alone and produces a significant decrease in chylomicron 
lipid content both at fasting and postprandially, a significant decrease in chylomicron 
postprandial apoB-48, and significant fasting and postprandial decreases in the 
cholesterol content of VLDL, IDL, and LDL [39]. Yunoki et al. have demonstrated 
that a 4-week treatment with ezetimibe suppressed the postprandial peaking of TG, 
remnant lipoprotein, and apoB-48. Furthermore, they have shown that FMD reduc-
tion, which signifies endothelial dysfunction, also decreased with treatment [40].
13. Conclusion
We recognize that postprandial dyslipidemia is an undertreated disorder. 
Although robust prospective clinical trials are lacking, there is still increasing evi-
dence of the clinical significance of postprandial dyslipidemia as a risk factor for CV 
disease. Clearly, postprandial elevations of lipids, specifically TG and TRLs, result 
to endothelial dysfunction and atherosclerosis. These result to increase in morbid-
ity and possible mortality due to cardiovascular diseases. This should translate to a 
paradigm shift in the diagnosis and treatment of dyslipidemia. Presently, statins, 
fibrates, ezetimibe, and orlistat in sequential or combination regimen or as needed 
(orlistat) are possible treatment options for postprandial dyslipidemia in addition to 
proper diet and exercise. However, studies that focus on treatment of postprandial 
lipemia with measurement of solid clinical outcomes such as cardiovascular events 
and mortality should be undertaken. Table 1 summarizes our recommendation.
Recommendations
Diagnosis • In addition to fasting lipid profile, postprandial lipid profile should also be determined, 
especially for patients at risk for cardiovascular disease
• In high-risk individuals such as those with diabetes mellitus and those with diagnosed 
cardiovascular disease, postprandial lipid profile should routinely be evaluated
• Postprandial lipid profile should include total cholesterol, TG, and HDL
Target • Postprandial values must approximate normal fasting levels
Treatment • Fibrates are the first-line drug of choice for postprandial lipemia with 
hypertriglyceridemia
• Elevated postprandial total cholesterol should be treated with high-intensity statin
• Ezetimibe can be considered if inadequately controlled by fibrates and statins
• Orlistat as needed may be taken prior to a fatty meal
Table 1. 
Summary of recommendations on the diagnosis and management of postprandial lipemia.
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